Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 73Ovarian Neoplasms 46Lung Neoplasms 26Breast Neoplasms 26Fallopian Tube Neoplasms 23Small Cell Lung Carcinoma 18Carcinoma, Ovarian Epithelial 16Squamous Cell Carcinoma of Head and Neck 14Neoplasms 14Glioblastoma 13Triple Negative Breast Neoplasms 12Recurrence 11Head and Neck Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Endometrial Neoplasms 10Uterine Cervical Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 8Hodgkin Disease 8Brain Neoplasms 8Lymphoma 7Esophageal Neoplasms 7Central Nervous System Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Glioma 6Esophageal Squamous Cell Carcinoma 6Astrocytoma 6Adenocarcinoma of Lung 6Mesothelioma 5

Interventions

Radiation 1Paclitaxel 1Chemoradiotherapy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Resectable Esophageal Cancer × Carboplatin × Clear all
NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

University of Wisconsin, Madison

Phase 1/2 Completed
22 enrolled 17 charts
Gastrointestinal

Resectable Esophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡